Few naming problems in Ayurvedic pharmacognosy are as persistent as the Brahmi–Mandukaparni confusion. In prescriptions, product labels, regional practice and household use, the word “Brahmi” may point to Bacopa monnieri, Centella asiatica, or a mixture of both. This matters because the two plants are botanically distinct, carry different pharmacognostic markers, and are used with different practical expectations in Ayurveda and in contemporary herbal practice.

The cleanest way to resolve the confusion is to keep the traditional name and the botanical name together. In current pharmacopoeial usage, Brahmi is Bacopa monnieri and Mandukaparni is Centella asiatica. Both are valuable medhya-type herbs, but they should not be treated as interchangeable without knowing exactly which plant is being used.

The Two Plants in Question

The following comparison gives the practical identification points most relevant for practitioners, students and consumers. It combines pharmacopoeial identity, plant morphology and modern marker-compound distinctions.

Where the Confusion Comes From

The confusion is not simply a modern marketing error. The Ayurvedic Pharmacopoeia of India itself shows why regional language can mislead. The Brahmi monograph for Bacopa monnieri includes vernacular names such as “Manduka Parni” in Hindi and “Mandukaparni” in Kannada, while the Mandukaparni monograph for Centella asiatica includes “Brahmi” in Hindi, Punjabi and Urdu, and “Brahmi soppu” in Kannada. In other words, the same vernacular names have crossed over between the two plants.

This is why the botanical name is not a minor technical detail. A label that says only “Brahmi” may still be ambiguous unless it states Bacopa monnieri, Centella asiatica, or both with quantities.

Classical Context

In the Rasayana chapter of the Charaka Samhita, Mandukaparni appears specifically in the medhya rasayana passage: Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice, and Shankhapushpi paste are named as rasayana preparations that support life, strength, agni, complexion, voice and medha. Brahmi also appears in Charaka in a separate rasayana context, including Aindra Rasayana. This supports the need to read the classical name in context rather than forcing every “Brahmi” and “Mandukaparni” reference into one plant.

Modern pharmacopoeial standardization resolves the practical dispensing question by assigning Brahmi to Bacopa monnieri and Mandukaparni to Centella asiatica. That is the safest convention for prescriptions, product labels, research reports and consumer guidance.

Pharmacognostic Differences

When the fresh plant is available, the difference is visible. Bacopa monnieri has small, opposite, fleshy leaves and a wetland habit. Centella asiatica has longer petioles and kidney-shaped to nearly circular leaves, arising from a creeping stoloniferous plant. Microscopic and phytochemical profiling also separates them clearly.

Why the Distinction Matters Clinically

Both herbs are used in mind-and-nervous-system contexts, but the practical emphasis differs. Bacopa monnieri is the plant most often examined in standardized oral extracts for cognitive performance, attention and memory-related outcomes. Centella asiatica has a strong identity in skin, connective tissue, wound support and venous microcirculation contexts, while also being used traditionally as a medhya herb.

Bacopa monnieri: Brahmi in Pharmacopoeial Usage

In the Ayurvedic Pharmacopoeia of India, Brahmi is defined as the dried whole plant of Bacopa monnieri. Its official Ayurvedic properties are madhura-tikta-kashaya rasa, laghu-sara guna, shita virya and madhura vipaka. The monograph lists medhya, rasayana, kaphahara, vatahara, ayushya and matiprada among its actions, and gives 1–3 g powder as the dose.

Contemporary Bacopa preparations usually specify bacoside content. Standardized extracts in adult trials commonly fall around 300–450 mg per day, while traditional crude-herb dosing is higher. Because Bacopa may cause gastrointestinal discomfort and mild sedation in some users, it is commonly taken with food and selected cautiously in people already using sedatives, anticholinergic drugs, thyroid medication or multiple prescription medicines.

Centella asiatica: Mandukaparni in Pharmacopoeial Usage

In the Ayurvedic Pharmacopoeia of India, Mandukaparni is defined as the dried whole plant of Centella asiatica. Its official Ayurvedic properties are tikta rasa, laghu-sara guna, shita virya and madhura vipaka. The API dose is 5–10 g of the dried drug.

Centella contains triterpenoid compounds such as asiaticoside, madecassoside, asiatic acid and madecassic acid. In practical use it is often associated with skin, wound, connective-tissue and venous applications, while in Ayurveda it also retains a medhya identity through Mandukaparni. It is also eaten as a food in some regions, but concentrated extracts should be treated differently from culinary use.

Safety Profiles: Key Differences

Correct identification matters because the two plants do not carry identical cautions. The following table summarizes practical safety distinctions without replacing individualized medical advice.

Dosage and Preparation: Do Not Transfer Doses Across Plants

A Bacopa dose should not be copied onto a Centella product, and a Centella triterpenic-fraction dose should not be copied onto a Bacopa product. The pharmacopoeial powder dose for Brahmi is 1–3 g, while the API dose for Mandukaparni is 5–10 g. Modern standardized extracts add another layer because the marker compounds and percentage standardizations differ.

• Brahmi powder: API dose is 1–3 g of Bacopa monnieri powder.
• Bacopa standardized extract: Adult trial and clinical-reference ranges commonly use 300–450 mg per day of extract standardized to bacosides or bacopa glycosides.
• Mandukaparni dried drug: API dose is 5–10 g of Centella asiatica.
• Centella triterpenic fraction: Venous microcirculation studies have used purified triterpenic fractions such as 60–120 mg daily under study conditions.

Traditional Formulations and Single-Herb Use

Brahmi and Mandukaparni appear in different practical formats. The API Brahmi monograph lists formulations such as Saraswatarishta, Brahmi Ghrita, Brahmi Vati, Sarasvata Churna and Smritisagara Rasa. For Mandukaparni, Charaka’s medhya rasayana passage specifically names Mandukaparni swarasa, or fresh juice, as the preparation in that context.

This distinction is useful at the prescription desk. If a clinician intends Brahmi Ghrita under the pharmacopoeial Brahmi identity, Bacopa monnieri is the expected plant. If the intended herb is Mandukaparni swarasa, the pharmacopoeial identity is Centella asiatica.

When Both Are Used Together

Some formulations and modern supplements use both Bacopa and Centella. That can be a deliberate choice, but it should be transparent. A combined product should state both botanical names and their respective quantities, rather than hiding the mixture under the single word “Brahmi.”

Using both herbs together does not remove the need for dose clarity. It increases the need for it, because each plant contributes its own constituents, actions and cautions.

Practical Recommendations for Consumers

The safest buying rule is simple: never rely on the name “Brahmi” alone. Look for the Latin botanical name, the part used, the extract ratio or standardization, the dose per serving, and quality-testing information.

• For Bacopa: the label should say Bacopa monnieri and, for extracts, ideally specify bacosides or bacopa glycosides.
• For Centella: the label should say Centella asiatica and, for extracts, ideally specify asiaticoside, madecassoside, total triterpenes or TTFCA-type standardization.
• For fresh herbs: Bacopa has small opposite fleshy leaves and a wetland habit; Centella has kidney-shaped leaves on longer petioles and creeps by stolons.
• For prescriptions: ask the practitioner whether the intended plant is Bacopa monnieri, Centella asiatica, or both.
• For children, pregnancy, breastfeeding, chronic illness or prescription medicines: use only under qualified professional guidance.

The Clean Resolution

The most practical resolution is not to argue over which regional usage is “wrong,” but to standardize communication. In current pharmacopoeial usage, write and dispense Brahmi (Bacopa monnieri) when Bacopa is intended, and Mandukaparni (Centella asiatica) when Centella is intended.

Both herbs have legitimate Ayurvedic value. The problem begins only when one name is used without botanical clarity. Accurate naming protects classical integrity, clinical intent, product quality and patient safety.

Medical Disclaimer: This article is for educational purposes only and does not replace individualized advice. Consult a qualified Ayurvedic practitioner or healthcare provider before using Brahmi, Mandukaparni or any concentrated herbal supplement, especially if you are pregnant, breastfeeding, giving it to a child, taking prescription medicines, or living with thyroid, liver, neurological or cardiovascular conditions.

References

1. Ayurvedic Pharmacopoeia of India
2. Ayurvedic Pharmacopoeia of India
3. Powo (powo.science.kew.org)
4. Powo (powo.science.kew.org)
5. Powo (powo.science.kew.org)
6. Powo (powo.science.kew.org)
7. Charaka Samhita — Rasayana Adhyaya
8. Phytopharmajournal (phytopharmajournal.com)
9. NCBI
10. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014), PubMed
11. NCBI
12. SAGE Journals
13. A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency (2013), PubMed Central
14. Hepatotoxicity associated with the ingestion of Centella asiatica (2005), PubMed
15. NCCIH

Sulforaphane from broccoli sprouts has become the star of functional-nutrition discussions around Nrf2, and deservedly so: it is among the most potent known Nrf2 activators, with supporting human trial data. But treating it as the only serious option creates a blind spot. Several Ayurvedic Rasayana herbs are studied as antioxidant-response modulators acting through distinct, and sometimes complementary, mechanisms. The evidence base for each differs in strength, and the honest comparison is one of mechanism and tradition — not of proven head-to-head superiority.

Nrf2 Biology: A Brief Mechanistic Overview

Under basal conditions, Nrf2 is held in the cytoplasm by Keap1, which targets it for proteasomal degradation. When cells encounter electrophilic or oxidative stress, specific cysteine residues on Keap1 are modified, releasing Nrf2 to translocate to the nucleus, bind ARE sequences, and drive expression of phase II detoxification enzymes and antioxidant proteins. This is more than simple free-radical scavenging: it is a sustained, genome-level upregulation of the cell’s own protective machinery, and a single exposure to a potent inducer can keep ARE-driven genes elevated for many hours. Many plant polyphenols engage this same pathway, and a number of them are concentrated in herbs Ayurveda classifies as Rasayana.

Curcumin (Haridra – Curcuma longa): The Most Studied Nrf2 Activator

Haridra (turmeric, Curcuma longa) contains curcumin, reported in preclinical studies to engage Nrf2 through several mechanisms: direct modification of Keap1 cysteine residues, PI3K/Akt-mediated phosphorylation, and MAPK-dependent nuclear translocation. Clinically, a 2019 meta-analysis of randomized controlled trials found that curcumin supplementation significantly reduced malondialdehyde (MDA) and raised superoxide dismutase (SOD), catalase, and glutathione peroxidase in people with disease-associated oxidative stress — a pattern consistent with antioxidant-response upregulation.

Bioavailability is the practical obstacle: unformulated curcumin has roughly 1% oral bioavailability. Here Ayurvedic pharmacy and modern pharmacology converge in an instructive way. Classical Ayurveda routinely pairs herbs with yogavahi (“catalyst”) substances such as Maricha (black pepper) and Pippali (Piper longum) — for example in the formulation Trikatu — to enhance the potency and absorption of co-administered drugs. Centuries later, Shoba and colleagues (Planta Medica, 1998) found that piperine increased curcumin bioavailability by as much as 2000% in human volunteers, largely by inhibiting glucuronidation. The classical texts did not, of course, describe Keap1 or Nrf2; what they encoded was an empirical absorption-enhancement principle that modern data later explained.

Practical doses for antioxidant effect: 500–1000 mg curcuminoids daily as a phytosome or piperine-enhanced formula; raw turmeric powder requires roughly 3–5 g for an equivalent curcuminoid load.

Bacopa monnieri (Brahmi): The Classical Medhya Rasayana

Brahmi (Bacopa monnieri) is one of Ayurveda’s foremost Medhya Rasayana herbs — those traditionally prescribed to support intellect, memory, and the nervous system. Its principal actives, the triterpene saponins bacoside A and bacoside B, show antioxidant activity in neuronal cell and animal models, including reduced lipid peroxidation and support of glutathione status; some preclinical reports also describe HO-1 induction, though direct human ARE-gene data in brain tissue are not available. Importantly, Bacopa’s cognitive benefits in humans are supported by several randomized controlled trials of standardized extract, which is the more robust part of its evidence base. For neuroprotective intent, its traditional standing and tissue-directed preclinical antioxidant signal are the realistic claims — not a demonstrated advantage over sulforaphane.

Amalaki (Emblica officinalis): The Supreme Rasayana

Amalaki (Indian gooseberry, Emblica officinalis) is Ayurveda’s most revered Rasayana, a component of Triphala and the principal ingredient of Chyawanprash. It is among the richest natural sources of vitamin C and also supplies hydrolysable tannoids — emblicanin A and B — together with ellagic acid, gallic acid, and quercetin. The tannoids are comparatively heat-stable, which offers a plausible traditional rationale for why cooked preparations such as Chyawanprash retain antioxidant activity that simple ascorbic acid would lose during processing. Preclinical studies broadly report antioxidant and hepatoprotective activity for Amalaki extracts, consistent with its classical use to support digestion, the liver, and healthy aging (Vayasthapana). (Note: older “ORAC-ratio” comparisons once cited for amla should be set aside — the USDA withdrew its ORAC database in 2012, stating the values have no established relevance to antioxidant effects in the body.)

Ashwagandha (Withania somnifera): Rasayana and Balya

Ashwagandha (Withania somnifera) is classically a Rasayana, Balya (strength-promoting), and Vajikarana herb, valued for restoring vitality in states of depletion, stress, and convalescence. Its withanolides — including withaferin A and withanolide D — show antioxidant and cytoprotective activity in cell and animal models. Proposals that withanolide D activates the mitochondrial deacetylase SIRT3 to stabilize Nrf2 should be treated as an unproven hypothesis: that link currently rests only on computational docking studies, with no published enzymatic or cell-based validation, and the relevant authors themselves note the lack of experimental confirmation. The defensible position is that Ashwagandha is a well-established adaptogenic Rasayana with preclinical antioxidant signals, plausibly complementary to polyphenol-based herbs that act more directly on Keap1.

Guduchi (Tinospora cordifolia): Amrita and Immune Rasayana

Guduchi (giloy, Tinospora cordifolia) carries the epithet Amrita (“nectar of immortality”) and is Ayurveda’s premier immune-supporting and Jvarahara (antipyretic) Rasayana. It contains tinosporin, columbin, syringin and related glycosides; in preclinical models these are associated with antioxidant activity alongside immunomodulation, a combination that fits its traditional use where inflammatory and oxidative stress coexist. One correction of a common error is warranted here: berberine is the signature alkaloid of Daruharidra (Berberis aristata), not Guduchi — Tinospora carries it only in trace amounts — so berberine should not be listed among Guduchi’s principal actives. Robust human ARE-pathway data for Guduchi are not yet available, so its standing rests on tradition and preclinical pharmacology.

Practical Synergistic Protocols

Because these herbs are believed to act through partially non-overlapping mechanisms, traditional and modern practice often combines them. The stacks below are evidence-informed and tradition-based suggestions, not validated clinical regimens, and should be adapted by a qualified practitioner.

Cognitive Support Stack

Brahmi 300 mg (bacosides ~20%) + Amalaki 500 mg (tannoid extract) + Curcumin 500 mg (piperine-enhanced), taken in the morning with food. The intent is to combine a classical Medhya herb (Brahmi) with a broad antioxidant Rasayana (Amalaki) and a well-studied systemic agent (curcumin).

Vitality and Recovery Stack

Ashwagandha 600 mg (KSM-66 or equivalent) + Shilajit 250 mg (purified/Shuddha) + Amalaki 500 mg, in the morning. This pairs an adaptogenic Rasayana (Ashwagandha) with traditional mineral-pitch (Shilajit) and an antioxidant fruit Rasayana (Amalaki) for states of fatigue and depletion.

Immune-Inflammatory Stack

Guduchi 400 mg extract + Curcumin 500 mg + Haritaki 500 mg, with meals. The aim is to combine an immune Rasayana (Guduchi), a systemic anti-inflammatory (curcumin), and a gut-directed Rasayana (Haritaki, also a member of Triphala).

For a deeper understanding of how these herbs interact with modern pharmacology and safety profiles, the herb-drug interactions guide provides essential reference. The classical theory connecting these plants to longevity is explored further in the Rasayana therapy longevity review.

Limitations and Research Gaps

Most Nrf2-pathway research on these herbs remains at the in vitro or animal level, and several mechanistic claims that circulate online — specific HO-1 fold-changes, named cell-line studies, or sirtuin links — do not hold up when traced back to the primary literature. Human studies showing direct ARE-gene expression changes in target tissues are scarce. The field needs standardized biomarkers (serum NQO1, urinary 8-OHdG, glutathione/GSSG ratio) applied consistently before dose-response relationships can be claimed with confidence. This is not an argument against using these herbs — their traditional use is long, their general safety is reasonable, and outcome-level clinical data exist for several — but an argument for precision: these are evidence-informed Rasayana interventions, not proven first-line treatments for conditions requiring established medical care.

References

1. Nrf2/Keap1/ARE signaling: Towards specific regulation (2022), PubMed Central
2. Curcumin reduces malondialdehyde and improves antioxidants in humans with diseased conditions: a comprehensive meta-analysis of randomized controlled trials (2019), PubMed Central
3. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

Neither herb can be described as universally superior. The more useful question is whether the principal concern is memory retention, stress-related mental fatigue, poor sleep, anxiety symptoms, or a medically significant change in cognition.

Different Evidence Profiles, Not Single Proven Mechanisms

The biological actions of both plants are complex. Human trials do not establish one exclusive mechanism for either herb, and mechanistic descriptions based on laboratory or animal experiments should not be treated as proven explanations of their clinical effects.

Bacopa monnieri contains bacosides and related dammarane-type triterpenoid saponins. Preclinical investigations have examined cholinergic and serotonergic signalling, antioxidant activity, neuronal communication, and amyloid-related pathways. These findings provide possible explanations for its effects, but they do not justify reducing Bacopa to a purely “cholinergic” medicine.

Ashwagandha contains withanolides, alkaloids, and other constituents whose concentrations differ between roots and leaves. Experimental work has investigated stress-response pathways, GABA-related signalling, inflammation, oxidative stress, and neuroprotection. In human studies, its clearest modern application is support for stress and sleep rather than a firmly established direct nootropic effect.

Ayurvedic Identity and Classical Context

The Ayurvedic Pharmacopoeia of India identifies Brahmi as the dried whole plant of Bacopa monnieri and Ashwagandha as the dried mature root of Withania somnifera. The pharmacopoeial profiles are not interchangeable and should not be replaced by the properties of similarly named plants or by descriptions created for modern supplements.

In the specific Medhya Rasayana passage of the Charaka Samhita, the four substances named are Mandukaparni, Yashtimadhu, Guduchi, and Shankhapushpi. That passage does not present Bacopa and Ashwagandha as a paired formula. Brahmi is nevertheless classified as medhya and rasayana in the Ayurvedic Pharmacopoeia, while Ashwagandha is classified as rasayana, balya, and vajikarana.

Clinical Evidence: Bacopa monnieri

Bacopa has been examined in several randomized trials lasting approximately two to three months. The most repeatable positive signal concerns delayed recall, retention of newly learned information, and selected measures of attention or processing speed. Results are not uniformly positive across every cognitive test.

Stough et al. (2001) enrolled 46 healthy adults in a double-blind, placebo-controlled trial. Participants received 300 mg daily of an extract standardized to approximately 55% combined bacosides for 12 weeks. Improvements were reported in visual-information-processing speed, learning rate, and memory consolidation, with the clearest effects appearing at the 12-week assessment rather than after five weeks.

Roodenrys et al. (2002) studied 76 adults aged 40–65 for three months. Bacopa improved retention of newly acquired information, apparently by reducing forgetting rather than increasing the initial learning rate. The trial did not demonstrate broad improvement in attention, short-term memory, working memory, or retrieval of information learned before treatment.

Peth-Nui et al. (2012) randomized 60 healthy older adults to placebo or Bacopa at 300 or 600 mg daily for 12 weeks. The investigators reported changes in attention, cognitive processing, and working-memory measures, together with changes in acetylcholinesterase activity. The modest sample and numerous measured outcomes make replication important.

Kongkeaw et al. (2014) reviewed nine randomized controlled trials involving 518 participants. The pooled results most clearly supported an improvement in speed of attention, including choice-reaction-time and Trail Making Test performance. A separate systematic review by Pase and colleagues found the most consistent cognitive signal in memory free recall, while results for other domains were less consistent.

These studies support Bacopa as the more directly investigated of the two herbs for chronic memory outcomes. They do not establish an immediate stimulant effect, prevention of dementia, or benefit for every person with forgetfulness.

Clinical Evidence: Ashwagandha

Ashwagandha has some cognition-focused human data, but the studies are fewer, use different plant parts and extracts, and include very different populations. Its broader clinical literature is more strongly centred on stress and sleep.

Choudhary et al. (2017) randomized 50 adults with mild cognitive impairment to placebo or 300 mg of Ashwagandha root extract twice daily for eight weeks. The treatment group improved on measures of immediate and general memory, executive function, sustained attention, and information-processing speed. Because the participants already had mild cognitive complaints, the results should not automatically be applied to healthy, unstressed adults.

Pingali et al. (2014) used a double-blind crossover design in 20 healthy men. Participants took two 250 mg capsules of a standardized root-and-leaf aqueous extract twice daily for 14 days. Reaction times improved in simple reaction, choice discrimination, digit-symbol substitution, digit vigilance, and card-sorting tasks, while finger-tapping performance did not change.

A systematic review of Ashwagandha for cognitive dysfunction identified a small and heterogeneous clinical literature involving healthy participants and people with cognitive or psychiatric conditions. Although several individual outcomes were favourable, the review called for larger and methodologically stronger trials. The U.S. National Center for Complementary and Integrative Health currently regards the evidence for cognitive function as insufficient for a firm conclusion.

Head-to-Head Comparison

There is no sound basis for assigning fixed labels such as “Bacopa for everyone with memory problems” or “Ashwagandha for everyone under stress.” The following comparison reflects the emphasis of the available human literature rather than a direct trial proving that one herb outperforms the other.

Which Is Better for What?

Selection should be based on the person’s symptoms, Ayurvedic assessment, medical history, medicines, digestive tolerance, and the exact preparation being considered. Neither herb should be chosen solely from an online “nootropic” ranking.

Consider Brahmi when memory is the principal concern

Brahmi is the more relevant candidate when the primary objective is gradual support for learning, retention, or delayed recall and when a qualified practitioner considers its cooling, light, and mobile pharmacopoeial qualities appropriate.

• The principal concern is retaining newly learned information.
• A chronic rather than immediately stimulating intervention is acceptable.
• The person can tolerate the possibility of gastrointestinal effects.
• The chosen product corresponds reasonably to a preparation studied in humans.

Consider Ashwagandha when stress or poor sleep is prominent

Ashwagandha may be more relevant when mental performance is being affected by persistent stress, poor sleep, fatigue, or anxiety symptoms and its warming, strengthening profile is suitable. Its role within a broader Ayurvedic protocol should still be individualized rather than assumed from a supplement label.

• Stress or sleep disturbance is a major part of the presentation.
• There is a simultaneous need for a traditional balya or rasayana approach.
• The person does not have a contraindication involving pregnancy, thyroid disease, autoimmune disease, liver concerns, surgery, or interacting medicines.
• The plant part and extract composition are clearly identified.

Rapid or progressive memory loss, confusion, personality change, language difficulty, impaired daily functioning, or new neurological symptoms requires medical assessment. Neither herb should be used to delay evaluation for dementia, depression, medication effects, thyroid disease, vitamin deficiency, sleep apnea, or another treatable condition.

Can Brahmi and Ashwagandha Be Combined?

A proprietary preparation containing both plants has been studied for stress-related outcomes, but this does not establish a universal cognitive protocol or prove that all Bacopa and Ashwagandha products can be combined safely. Extract composition, dose, plant part, concurrent medicines, and the individual’s constitution can substantially change the clinical situation.

The specific Charaka Samhita passage on four Medhya Rasayana drugs is not evidence for a classical Brahmi–Ashwagandha pair. An individualized Medhya Rasayana programme may contain more than one medicine, but its formulation, vehicle, diet, and duration should be selected by a qualified Ayurvedic practitioner.

When both are considered, introducing one preparation at a time makes adverse effects and individual responses easier to recognize. Fixed instructions such as “Bacopa every morning and Ashwagandha every night” are not established classical rules and should not replace personalized prescribing.

Important Safety and Quality Caveats

Bacopa commonly causes gastrointestinal symptoms such as nausea, abdominal cramping, and increased stool frequency. Its cholinergic activity creates potential concerns with cholinergic or anticholinergic medicines. Caution is also appropriate in people with bradycardia, gastrointestinal obstruction or ulcer disease, and thyroid conditions. Animal findings suggest a possible effect on thyroid hormone, although its clinical significance in humans remains uncertain.

Ashwagandha can cause drowsiness and gastrointestinal upset. Rare cases of liver injury have been associated with supplements. It should be avoided during pregnancy and breastfeeding and used cautiously around surgery or in people with thyroid or autoimmune disorders. Potential interactions include sedatives, anticonvulsants, immunosuppressants, thyroid hormone, and medicines for blood pressure or diabetes.

Standardization percentages cannot be compared without knowing which compounds were measured and by what analytical method. Whole-plant Brahmi powder is not equivalent to a concentrated Bacopa extract, and Ashwagandha root powder is not equivalent to a root-and-leaf extract. Findings from a branded or chemically defined extract apply most directly to that preparation and should not be transferred automatically to every product carrying the same herb name.

Consult a qualified Ayurvedic practitioner and healthcare provider before using either herb, particularly when taking prescription medicines or when pregnant, breastfeeding, preparing for surgery, or managing thyroid, liver, autoimmune, cardiac, gastrointestinal, neurological, or psychiatric conditions. Sleep, physical activity, adequate nutrition, hearing and vision care, social engagement, and management of cardiovascular risk remain central to long-term brain health.

References

1. Ayurvedic Pharmacopoeia of India
2. Ayurvedic Pharmacopoeia of India
3. Charaka Samhita — Rasayana Adhyaya
4. Neuropharmacological review of the nootropic herb Bacopa monnieri (2013), PubMed Central
5. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects (2001), PubMed
6. Chronic effects of Brahmi (Bacopa monnieri) on human memory (2002), PubMed
7. Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers (2012), PubMed Central
8. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014), PubMed
9. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials (2012), PubMed
10. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions (2017), PubMed
11. Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants (2014), PubMed Central
12. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study (2019), PubMed
13. A systematic review of the clinical use of Withania somnifera (Ashwagandha) to ameliorate cognitive dysfunction (2020), PubMed
14. NCCIH
15. NCBI
16. Impact of a Withania somnifera and Bacopa monnieri Formulation on SH-SY5Y Human Neuroblastoma Cells Metabolism Through NMR Metabolomic (2024), PubMed Central